An Open Label, Multicenter, Single Arm Study of Pasireotide LAR in Patients With Rare Tumors of Neuroendocrine Origin
An Open Label, Multicenter, Single Arm Study of Pasireotide LAR in Patients With Rare Tumors of Neuroendocrine Origin
This study will assess the effectiveness and safety of pasireotide long-acting release in patients who have rare tumors of neuroendocrine origin.
Inclusion Criteria:
Male and Female Patients at least 18 years old
Patient who have rare tumors of neuroendocrine origin, such as tumors of the:
Patients who have failed standard of care treatment or for whom no standard of care treatment exist
Signed Informed Consent
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply.
Boston, Massachusetts 02215, United States
Buenos Aires, Buenos Aires C1264AAA, Argentina